Kodiak Sciences (NASDAQ:KOD - Get Free Report) had its price objective raised by stock analysts at UBS Group from $3.00 to $5.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a "neutral" rating on the stock. UBS Group's price objective points to a potential upside of 22.55% from the company's previous close.
Several other analysts have also issued reports on the company. Barclays boosted their target price on Kodiak Sciences from $2.00 to $3.00 and gave the company an "underweight" rating in a research note on Monday. The Goldman Sachs Group restated a "sell" rating and issued a $2.00 target price on shares of Kodiak Sciences in a research note on Monday, December 11th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $6.40.
Check Out Our Latest Research Report on KOD
Kodiak Sciences Stock Down 4.4 %
Kodiak Sciences stock traded down $0.19 during mid-day trading on Thursday, reaching $4.08. 764,365 shares of the company's stock were exchanged, compared to its average volume of 899,447. The business's fifty day simple moving average is $5.42 and its 200 day simple moving average is $3.46. The firm has a market capitalization of $214.24 million, a PE ratio of -0.89 and a beta of 2.15. Kodiak Sciences has a one year low of $1.37 and a one year high of $9.80.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Point72 Middle East FZE purchased a new stake in Kodiak Sciences during the 4th quarter valued at $27,000. Tower Research Capital LLC TRC boosted its stake in Kodiak Sciences by 1,173.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 16,994 shares of the company's stock valued at $31,000 after purchasing an additional 15,660 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Kodiak Sciences during the 3rd quarter valued at $37,000. American Century Companies Inc. boosted its stake in Kodiak Sciences by 41.1% during the 3rd quarter. American Century Companies Inc. now owns 20,654 shares of the company's stock valued at $37,000 after purchasing an additional 6,013 shares during the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Kodiak Sciences during the 4th quarter valued at $41,000. Institutional investors own 89.06% of the company's stock.
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Articles
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
